Clinical trials: Glioblastoma by Gene Expression Profile

Melanoma (Skin), Melanoma Recurrent

Expanded Access for Pembrolizumab (MK-3475)

• No Longer Available
• Age: 18 to 80 years
• Expanded access

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors.

Conditions

Melanoma (Skin), Melanoma Recurrent, Glioblastoma Multiforme, Glioblastoma by Gene Expression Profile

Trial name

NCT03311542

Testing

pembrolizumab

Where

4 sites in Belarus, Hong Kong and 2 more

Sponsor

Center Trials & Treatment